Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 2,210,000 shares, a growth of 5.2% from the December 31st total of 2,100,000 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily trading volume, of 875,000 shares, the short-interest ratio is presently 2.5 days.

Analysts Set New Price Targets

CMPX has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Compass Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.80.

Institutional Investors Weigh In On Compass Therapeutics

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in shares of Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after purchasing an additional 356,352 shares during the last quarter. Barclays PLC increased its position in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after purchasing an additional 3,822 shares during the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Trading Up 6.6 %

Shares of NASDAQ:CMPX opened at $3.22 on Monday. The stock’s fifty day simple moving average is $1.90 and its two-hundred day simple moving average is $1.64. Compass Therapeutics has a 1-year low of $0.76 and a 1-year high of $3.63. The stock has a market cap of $443.04 million, a PE ratio of -8.70 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, sell-side analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.